A crystal form of lysine acetate and preparation method thereof

By adjusting the preparation conditions of lysine acetate, crystallization and washing with a mixed acetonitrile solution, a new crystal form of lysine acetate was prepared, which solved the problem of short shelf life caused by lysine acetate soluble and hygroscopicity, and significantly improved the Its stability and dissolution time extend the shelf life.

CN116283633BActive Publication Date: 2024-12-06YICHANG SANXIA PUNUODING BIOPHARMACEUTICS CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310118174.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-15
Publication Date
2024-12-06
Estimated Expiration
2043-02-15

AI Technical Summary

Technical Problem

Lysine acetate is easily soluble in water and has strong hygroscopicity, resulting in a short shelf life. It is only one year under conventional storage conditions, and is prone to dehydration and deterioration, limiting its market application.

Method used

By adjusting the preparation conditions of lysine acetate, crystallization and washing with a mixed acetonitrile solution, a new type of lysine acetate crystal form was prepared. The appearance of this crystal form is white, pearly, sandy grainy, significantly improving Dissolution time and stability reduce moisture-induced properties and extend shelf life.

Benefits of technology

The dissolution time of the new lysine acetate crystal form was extended to about 2 times, and the moisture-induced weight gain was reduced from 23.4% to 4.8%-6.6%, ensuring lower moisture content of the product, more stable properties, and extended shelf life to more than two years. , reducing storage and transportation requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116283633B_ABST
    Figure CN116283633B_ABST
Patent Text Reader

Abstract

The invention provides a crystal form of lysine acetate and a preparation method thereof. Two new crystal forms of lysine acetate are prepared by a mixed solvent-recrystallization method. The new crystal forms have characteristic peaks at 6.931±0.2, 13.826±0.2 and 18.337±0.2 in X-ray powder diffraction, and also have characteristic peaks at 21.495±0.2 and 24.170±0.2, and further have characteristic peaks at 27.327±0.1, 28.423±0.1, 30.711±0.1 or 21.914±0.1. The two crystal forms of lysine acetate have larger particles, significantly prolonged dissolution time, and significantly reduced hygroscopicity, thereby ensuring a lower water content of the lysine acetate product, not being easily affected by moisture and deteriorating during long-term storage, having more stable properties, and greatly prolonging the shelf life.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of amino acid raw material drug preparation, and particularly relates to a crystal form of lysine acetate and a preparation method thereof. Background Art

[0002] Lysine Acetate, molecular formula is C6H 14 N2O2·C2H4O2 is the acetate form of lysine. Lysine is one of the essential alkaline amino acids for the human body and is also the first limiting amino acid. Lysine can promote human development, enhance immunity, improve insomnia, improve memory, help calcium absorption, treat and prevent osteoporosis, and reduce the level of triglycerides in the blood, but the body cannot synthesize lysine by itself and must be supplemented from physical objects. Lysine is mainly found in animal foods and beans. The lysine content in cereal foods is extremely low, so it is easy to suffer from lysine deficiency. Symptoms of lysine deficiency include fatigue, weakness, nausea, vomiting, dizziness and loss of appetite, developmental delay, anemia, etc. In order to alleviate and treat the above symptoms, lysine needs to be supplemented through in vitro injection, oral administration, etc. However, free lysine is unstable and easily absorbs carbon dioxide in the air. Therefore, products that supplement lysine are often prepared in the form of lysine salts. Lysine acetate is a lysine salt that is easily absorbed and utilized by the human body.

[0003]

[0004] Due to the poor chemical stability of lysine, it was mostly used in the preparation of lysine hydrochloride in the early days. The compound amino acid infusion prepared with lysine hydrochloride has a high chloride ion content, which some patients cannot adapt to and is prone to hyperchloremia metabolic acidosis. Therefore, lysine acetate is currently more used to prepare amino acid injections and oral preparations. It can also be used as an auxiliary drug for diuretics, can treat lead poisoning caused by reduced chloride in the blood, and can also form salts with acidic drugs to reduce adverse reactions. It has a wide range of uses in medicine, so the market demand for lysine acetate raw materials is very large.

[0005] However, lysine acetate is easily soluble in water and has strong hygroscopicity. When the relative humidity exceeds 60%, it is easy to turn yellow and deteriorate, resulting in a short shelf life of lysine acetate. Under conventional storage, the shelf life is generally only about one year. If it is stored in a room temperature, light-shielded, sealed, and dry environment, the shelf life can be appropriately extended, but it needs to be used as soon as possible after the package is opened, otherwise it will deliquesce and deteriorate. This also puts high requirements on the storage environment, packaging quality and type, transportation, and application, which greatly limits the market of lysine acetate. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a crystal form of lysine acetate and a preparation method thereof. The appearance of the new crystal form of lysine acetate is usually white sandy granular crystals with pearl luster, and is significantly different from the performance of products prepared by conventional methods in terms of solubility and hygroscopicity. Through stability research, it is proved that the shelf life of lysine acetate of this crystal form can be extended to more than two years.

[0007] The technical solution adopted by the present invention is as follows:

[0008] The invention provides a crystal form of lysine acetate. Using Cu-Kα radiation, in an X-ray powder diffraction image, the 2θ values ​​of the crystal form have characteristic peaks at 6.931±0.2, 13.826±0.2 and 18.337±0.2.

[0009] Preferably, in the X-ray powder diffraction image of the lysine acetate crystal form, its 2θ value also has characteristic peaks at 21.495±0.1 and 24.170±0.2.

[0010] Further preferably, in the X-ray powder diffraction image of the lysine acetate crystal form, its 2θ value also has a characteristic peak at 21.914±0.1.

[0011] Further preferably, in the X-ray powder diffraction image of the lysine acetate crystal form, its 2θ value also has characteristic peaks at 27.327±0.1, 28.423±0.1, and 30.711±0.1.

[0012] Preferably, the lysine acetate crystal form has an absorption peak within 197° C.-200° C. in DSC analysis.

[0013] The present invention also provides a method for preparing a crystalline form of lysine acetate, characterized in that it comprises the following steps:

[0014] (1) Dissolve the crude lysine acetate in water, mix well, and then heat under vacuum and concentrate until the solution begins to turn yellow;

[0015] (2) adding the mixed solvent dropwise while hot, mixing well and leaving at room temperature until crystals precipitate;

[0016] (3) Filter by suction, and then wash with a mixed solvent for 1-3 times to obtain lysine acetate crystals.

[0017] Preferably, the temperature of the vacuum heating concentration in step (1) is 60-70°C, the vacuum degree is -0.08-0.1 MPa, and the rotation speed is 10-25 Hz; more preferably, the temperature is 65°C, the vacuum degree is -0.1 MPa, and the rotation speed is 12-18 Hz.

[0018] Preferably, the amount of the mixed solvent added in step (2) is 30% to 40% of the volume of the solution.

[0019] Preferably, the mixed solvent in steps (2) and (3) is a solution containing tetrahydrofuran or a solution containing acetonitrile.

[0020] Preferably, the solution containing tetrahydrofuran is a solution of tetrahydrofuran mixed with any one of water, anhydrous ethanol, isopropanol, and acetone, wherein the content of tetrahydrofuran is 20%-70%; the solution containing acetonitrile is a solution of acetonitrile mixed with any one of water, anhydrous ethanol, and methanol, wherein the content of acetonitrile is 10%-70%.

[0021] The beneficial effects of the present invention are as follows: the present invention adjusts the preparation conditions of lysine acetate, uses an acetonitrile mixed solution for crystallization and washing, and prepares a new crystal form of lysine acetate, the appearance of the new crystal form is white sandy granular crystals with pearl luster, and the dissolution time of the lysine acetate product is extended to about 2 times, and the weight gain due to moisture absorption is reduced from 23.4% to 4.8%-6.6%, thereby ensuring a lower water content of the product, and the product is not easily depreciated due to moisture, so that the properties of the lysine acetate raw material are more stable during the storage period and the shelf life is extended. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is the X-ray powder diffraction pattern of the lysine acetate crystal prepared in Example 1.

[0023] Figure 2 This is the DSC spectrum of the lysine acetate crystal prepared in Example 1.

[0024] Figure 3 This is the X-ray powder diffraction pattern of the lysine acetate crystal prepared in Example 5.

[0025] Figure 4 This is the DSC spectrum of the lysine acetate crystal prepared in Example 5.

[0026] Figure 5 The X-ray powder diffraction pattern of the lysine acetate crystal prepared in Comparative Example 1. DETAILED DESCRIPTION

[0027] The technical scheme of the present invention is further described in detail below in conjunction with specific embodiments and drawings. It should be understood that the following embodiments are only preferred embodiments of the present invention and should not be regarded as limitations of the present invention. The protection scope of the present invention shall be subject to the contents recorded in the claims. Those skilled in the art who make equivalent substitutions and modifications to the technical scheme of the present invention without making creative work shall fall within the protection scope of the present invention.

[0028] In the following examples, crude lysine acetate was produced in-house by our company.

[0029] Example 1

[0030] (1) Dissolve 5 g of crude lysine acetate in 100 mL of water, stir evenly, and concentrate under vacuum heating (65°C, -0.1 MPa, 15 Hz) until the solution begins to turn yellow;

[0031] (2) while hot, dropwise add 33 mL of 30% acetonitrile aqueous solution, stir evenly, and let stand at room temperature until crystals precipitate;

[0032] (3) Filter by suction, and wash twice with 30% by mass acetonitrile aqueous solution to obtain lysine acetate crystals.

[0033] The prepared lysine acetate crystal was subjected to X-ray powder diffraction and DSC scanning. The powder diffraction conditions were at room temperature and monochromatic Cu-Kα rays were used to irradiate the sample. The results are as follows:

[0034] Table 1 Diffraction data of lysine acetate crystals prepared in Example 1

[0035] peak 2θ angle D value I value 1 6.931 12.743 3089 2 13.826 6.3995 8737 3 18.337 4.8341 16062 4 21.495 4.1306 927 5 24.170 3.6744 1015 6 27.327 3.2608 1478 7 28.423 3.1376 1103 8 30.711 2.9089 1412

[0036] From Table 1 and Figure 1 The results show that the prepared lysine acetate crystal has 8 characteristic peaks in X-ray powder diffraction ( Figure 1 ), wherein the 2θ values ​​of the three strongest peaks are 18.337±0.1, 13.826±0.1, and 6.931±0.1, respectively; the lysine acetate crystal has an absorption peak at 199.88±0.1 in the DSC scanning spectrum, indicating that its complete melting temperature is 199.88±0.1℃( Figure 2 ).

[0037] Example 2

[0038] (1) Dissolve 5 g of crude lysine acetate in 100 mL of water, stir evenly, and concentrate under vacuum heating (65°C, -0.08 MPa, 18 Hz) until the solution starts to turn yellow;

[0039] (2) while hot, add 33 mL of acetonitrile-anhydrous methanol solution (the mass fraction of acetonitrile is 67%) dropwise, stir evenly and let stand at room temperature until crystals precipitate; (3) filter with suction and add acetonitrile-methanol solution (the mass fraction of acetonitrile is 67%) to wash twice to obtain lysine acetate crystals, which are subjected to X-ray powder diffraction and DCS scanning. The results are the same as those in Example 1.

[0040] Example 3

[0041] (1) Dissolve 5 g of crude lysine acetate in 100 mL of water, stir evenly, and concentrate under vacuum heating (60°C, -0.09 MPa, 25 Hz) until the solution begins to turn yellow;

[0042] (2) while hot, add 33 mL of acetonitrile-anhydrous ethanol solution (the mass fraction of acetonitrile is 43%) dropwise, stir evenly, and let stand at room temperature until crystals precipitate;

[0043] (3) Filtration and washing twice with acetonitrile-anhydrous ethanol solution (the mass fraction of acetonitrile is 43%) to obtain lysine acetate crystals, which were subjected to X-ray powder diffraction and DCS scanning. The results were the same as those in Example 1.

[0044] Example 4

[0045] (1) Dissolve 5 g of crude lysine acetate in 100 mL of water, stir evenly, and concentrate under vacuum heating (65°C, -0.1 MPa, 12 Hz) until the solution begins to turn yellow;

[0046] (2) while hot, dropwise add 33 mL of a 20% by mass aqueous solution of tetrahydrofuran, stir evenly, and then allow to stand at room temperature until crystals precipitate;

[0047] (3) Filter by suction, and wash twice with a 20% by mass aqueous solution of tetrahydrofuran to obtain a crystalline form of lysine acetate.

[0048] The prepared lysine acetate crystal was subjected to X-ray powder diffraction and DSC scanning. The powder diffraction conditions were at room temperature and monochromatic Cu-Kα rays were used to irradiate the sample. The results are as follows:

[0049] Table 2 Diffraction data of lysine acetate crystals prepared in Example 6

[0050] peak 2θ angle d value I value 1 7.028 12.568 6658 2 13.923 6.3553 1352 3 18.176 4.8766 4484 4 21.334 4.1614 1315 5 21.914 4.0526 1626 6 24.105 3.6889 3699

[0051] From Table 2 and Figure 3 The results show that the prepared lysine acetate crystal has 6 characteristic peaks ( Figure 3 ), the 2θ values ​​of the three peaks are 7.028±0.1, 18.176±0.1, and 24.105±0.1 respectively; and compared with Table 1, there are three less characteristic peaks at 27.327±0.1, 28.423±0.1, and 30.711±0.1, and one more characteristic peak at 21.914±0.1. The commercially available lysine acetate product has only two characteristic peaks, which are 7.124±0.1 and 24.202±0.1 ( Figure 5 The lysine acetate crystal has an absorption peak at 197.94±0.1 in the DSC scanning spectrum, indicating that its complete melting temperature is 199.88±0.1℃( Figure 4 ).

[0052] Example 5

[0053] (1) Dissolve 5 g of crude lysine acetate in 100 mL of water, stir evenly, and concentrate under vacuum heating (65°C, -0.1 MPa, 10 Hz) until the solution begins to turn yellow;

[0054] (2) while hot, add 33 mL of tetrahydrofuran-anhydrous ethanol solution (the mass fraction of tetrahydrofuran is 50%) dropwise, stir evenly, and let stand at room temperature until crystals precipitate;

[0055] (3) Filtration and washing twice with a tetrahydrofuran-anhydrous ethanol solution (the mass fraction of tetrahydrofuran is 50%) to obtain a crystalline form of lysine acetate. X-ray powder diffraction and DCS scanning were performed on the crystalline form, and the results were the same as those in Example 4.

[0056] Example 6

[0057] (1) Dissolve 5 g of crude lysine acetate in 100 mL of water, stir evenly, and concentrate under vacuum heating (60°C, -0.09 MPa, 15 Hz) until the solution starts to turn yellow;

[0058] (2) while hot, add 33 mL of tetrahydrofuran-anhydrous isopropanol solution (the mass fraction of tetrahydrofuran is 67%) dropwise, stir evenly, and let stand at room temperature until crystals precipitate;

[0059] (3) Filtration with suction, and washing twice with tetrahydrofuran-isopropanol solution (the mass fraction of tetrahydrofuran is 67%) to obtain lysine acetate crystal form, and performing X-ray powder diffraction and DCS scanning on the crystal form, the results are the same as those in Example 4.

[0060] Example 7

[0061] (1) Dissolve 5 g of crude lysine acetate in 100 mL of water, stir evenly, and concentrate under vacuum heating (70°C, -0.08 MPa, 20 Hz) until the solution begins to turn yellow;

[0062] (2) while hot, add 33 mL of tetrahydrofuran-anhydrous acetone solution (the mass fraction of tetrahydrofuran is 57%) dropwise, stir evenly, and let stand at room temperature until crystals precipitate;

[0063] (3) Filtration and washing twice with tetrahydrofuran-acetone solution (the mass fraction of tetrahydrofuran is 50%) to obtain lysine acetate crystals, which were subjected to X-ray powder diffraction and DCS scanning. The results were the same as those in Example 4.

[0064] Comparative Example 1

[0065] (1) Take 5 g of crude lysine acetate and add it to 100 mL of aqueous solution. After stirring evenly, heat under vacuum (70°C, -0.08 MPa, 20 Hz) and concentrate until the color of the solution begins to turn yellow;

[0066] (2) while hot, add 33 mL of anhydrous ethanol solution dropwise, and let the solution stand at room temperature until crystals precipitate;

[0067] (3) Filter by suction, and wash twice with anhydrous ethanol solution to obtain lysine acetate crystal form (powdered product).

[0068] In order to make the results of X-ray powder diffraction more accurate, the above reagents are preferably products with higher purity to reduce interference from impurities.

[0069] Example 8

[0070] 1.0 g of lysine acetate prepared in Example 1 and Example 4 and commercially available lysine acetate were respectively placed in a beaker, 100 mL of purified water was added, and the mixture was manually shaken for 2 seconds. The dissolution time was measured. The results are shown in Table 3:

[0071] Table 3 Solubility of different lysine acetates

[0072] Crystal form Time (seconds) Prolonged dissolution time Example 1 19.45 91.2% Example 6 19.89 95.6% Comparative Example 1 10.17 -

[0073] The results show that compared with the lysine acetate in Comparative Example 1, the dissolution time of the lysine acetate prepared in Example 1 and Example 6 is significantly prolonged, almost twice the dissolution time of commercially available lysine acetate, indicating that the lysine acetate crystals prepared in Example 1 and Example 4 have relatively poor solubility and are not easily affected by moisture and deteriorated during storage, thus extending the shelf life.

[0074] Example 9

[0075] The same mass of lysine acetate prepared in Example 1, Example 4 and Comparative Example 1 was accurately weighed and placed in an artificial climate box (set temperature of 25°C ± 1°C, relative humidity of 80% ± 2%) for hygroscopicity test. For detailed operation and judgment criteria, see the Guiding Principles for Hygroscopicity Test of Drugs in Part IV 9103 of the 2020 Edition of the Chinese Pharmacopoeia. The test results are shown in Table 4:

[0076] Table 4 Hygroscopicity of different lysine acetates

[0077]

[0078] As shown in Table 4, the water content of the lysine acetate prepared in Comparative Example 1 increased by 23.4% in 15 days during the storage period of up to 15 days, which is very hygroscopic. The water content of the lysine acetate prepared in Example 1 and Example 4 is basically balanced, and only increased by 5.8%-6.6%, indicating that the lysine acetate prepared in Comparative Example 1 is prone to drug dilution, deliquescence, deterioration and the like under high humidity conditions, which greatly shortens the shelf life. The lysine acetate prepared in Example 1 and Example 4 is hygroscopic, but the increase is not obvious during long-term storage, which is much lower than that in Comparative Example 1. At the same time, the hygroscopicity is caused by the chemical properties of the lysine acetate product itself. Therefore, the lysine acetate crystal prepared by the present invention has better stability in a humid environment, indicating that it has better storage resistance and can effectively extend the shelf life of the product.

[0079] Example 10

[0080] According to the method for determining bulk density and tap density in Part IV of the Chinese Pharmacopoeia 2020, the bulk density and tap density of lysine acetate prepared in Example 1, Example 4 and Comparative Example 1 were tested (using a 100 mL measuring cylinder). The results are shown in Table 5:

[0081] Table 5 Bulk density and tap density of different lysine acetates

[0082] Crystal form Bulk density Tap density Example 1 <![CDATA[6.80g / cm 3 ]]> <![CDATA[6.48g / cm 3 ]]> Example 4 <![CDATA[6.92g / cm 3 ]]> <![CDATA[6.55g / cm 3 ]]> Comparative Example 1 <![CDATA[7.28g / cm 3 ]]> <![CDATA[8.50g / cm 3 ]]>

[0083] The results show that compared with the lysine acetate product prepared in Comparative Example 1, the bulk density and tap density of the lysine acetate prepared in Example 1 and Example 4 are lower, indicating that their volumes are larger, indicating that the particles of the prepared lysine acetate crystals are larger, and in the process of feeding lysine acetate to prepare other products, the probability of dust generation is lower, and the impact on the production environment is smaller.

Claims

1. A crystalline form of lysine acetate, characterized in that: Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic peaks at 2θ values ​​of 6.931±0.2, 13.826±0.2, and 18.337±0.

2.

2. A crystalline form of lysine acetate according to claim 1, characterized in that: In the X-ray powder diffraction image of the lysine acetate crystal form, its 2θ value also has characteristic peaks at 21.495±0.2 and 24.170±0.

2.

3. A crystalline form of lysine acetate according to claim 2, characterized in that: In the X-ray powder diffraction image of the lysine acetate crystal form, its 2θ value also has a characteristic peak at 21.914±0.

1.

4. A crystalline form of lysine acetate according to claim 2, characterized in that: In the X-ray powder diffraction image of the lysine acetate crystal form, its 2θ value also has characteristic peaks at 27.327±0.1, 28.423±0.1, and 30.711±0.

1.

5. A crystalline form of lysine acetate according to any one of claims 1 to 4, characterized in that: The lysine acetate crystal form has an absorption peak within 197° C.-200° C. in DSC analysis.

6. A method for preparing the crystal form of lysine acetate according to any one of claims 1 to 5, characterized in that: The following steps are involved: (1) Dissolve the crude lysine acetate in water, mix well, and then heat and concentrate under vacuum until the solution begins to turn yellow; (2) Add the mixed solvent dropwise while hot, mix well and let stand at room temperature until crystals precipitate; (3) Filter by suction, and then wash with a mixed solvent for 1-3 times to obtain lysine acetate crystals.

7. The method according to claim 6, characterized in that: The temperature of the vacuum heating concentration in step (1) is 60-70° C., the vacuum degree is -0.08-0.1 MPa, and the rotation speed is 10-25 Hz.

8. The method according to claim 7, characterized in that: The temperature of the vacuum heating concentration is 65°C, the vacuum degree is -0.1MPa, and the rotation speed is 12-18Hz.

9. The method according to claim 6, characterized in that The amount of the mixed solvent added in step (2) is 30%-40% of the volume of the solution.

10. The method according to claim 6, characterized in that: The mixed solvent in steps (2) and (3) is a solution containing tetrahydrofuran or a solution containing acetonitrile.

11. The method according to claim 10, characterized in that: The solution containing tetrahydrofuran is a solution of tetrahydrofuran mixed with any one of water, anhydrous ethanol, isopropanol and acetone, wherein the content of tetrahydrofuran is 20%-70%; the solution containing acetonitrile is a solution of acetonitrile mixed with any one of water, anhydrous ethanol and methanol, wherein the content of acetonitrile is 10%-70%.

Citation Information

Patent Citations

  • Preparation method of DL-lysine

    CN104478746A

  • Preparation method of bulk drug of lysine acetate

    CN104829477A

  • Production technology for L-lysine acetate

    CN104892439A

  • Lysine hydrochloride compound and pharmaceutical composition thereof

    CN111116392A